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Long-term survival in patients with 
NSCLC treated with single-fraction vs. 
multi-fraction palliative radiotherapy 
in the case of lung tumour, brain 
metastases and bone metastases 
ABSTRACT
Background: Patients with advanced non-small cell lung cancer (NSCLC) are candidates for different types 
of treatment, including chemotherapy and radiotherapy or supportive care. Despite the fatal prognosis 
in advanced disease, many experienced radiation oncologists will apply radiation at low doses with the 
intention of palliative care. 
Methods: We used an extensive database of medical patients diagnosed with NSCLC, treated with palliative 
radiotherapy at the Oncology Centre in Bydgoszcz, from June 1998 to December 2013. A group of 3202 
patients was divided into subgroups: Group A)1762 patients irradiated on the lung tumor (without distant 
metastases): Total dose: A1) 6Gy/1 fr. (n = 19); A2) 8Gy/1fr. (n = 276); A3) 20Gy/5fr. (n = 1349); A4) 
30Gy/10fr.(n = 118). Group B) 548 patients irradiated on the central nervous system (CNS) metastases: 
B1) 20Gy/5fr. (n = 476); B2) 30Gy/10fr. (n = 72). Group C) 892 patients irradiated on the bone metastases: 
C1) 8Gy/1fr. (n = 452); C2) 10Gy/1fr. (n = 30); C3) 20Gy/5fr. (n = 341); C4) 30Gy/10fr. (n = 69). 
Results: Patients with irradiation of a lung tumour: The longest OS was observed in the group of patients 
irradiated with doses of 20 Gy (76%) and 30 Gy (7%). Patients with irradiation of bone metastases: No 
significant differences in OS were observed between the employed fractionation regimens. Patients with 
irradiation of CNS metastases: The choice of a higher dose of radiation therapy did not demonstrate 
differences in median OS values compared to a lower dose. 
Conclusions: The patients who were prescribed single fraction palliative radiotherapy did not have poorer 
prognoses or experience shorter survival than patients who were prescribed multi-fraction pRT in the case 
of lung tumour, brain metastases and bone metastases.
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INTRODUCTION 
Non-small cell lung carcinoma (NSCLC) represents 
approx. 85% of cases of lung cancer, with more than half 
of the patients having distant metastases at diagnosis 
[1]. Patients with advanced NSCLC are candidates 
for various therapies, including chemotherapy [2–3], 
radiation therapy [4–5] and life-supporting therapy [6]. 
Despite the fatal prognosis in advanced disease, many 
experienced oncologists will apply low-dose radiation 
therapy with palliative intent. The choice of an effective 
radiation dose that will not cause significant complica-
tions remains discussible. 
In our study, we conducted a retrospective analysis of 
the effectiveness of palliative radiation therapy in 3202 pa-
tients with advanced NSCLC using different methods of 
radiation dose fractionation depending on the location of 
lesions (lung tumour, bone metastases, CNS metastases).
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Material and methods
Patient database
An extensive medical database of patients treated 
at the Oncology Center in Bydgoszcz, Poland, was em-
ployed. The analysis included patients diagnosed with 
advanced NSCLC with no prior surgical intervention, 
treated with palliative radiation therapy between June 
1998 and December 2013. 
A group of 3202 patients was divided into three sub-
groups:
A) 1762 patients subjected to primary irradiation of 
a lung tumour (with no distant metastases revealed 
in imaging) 
A-1) within this group, 658 patients received chemo-
therapy after radiation therapy 
B) 548 patients subjected to primary irradiation of 
brain metastases
C) 892 patients subjected to irradiation of bone me-
tastases
Data collected from all patients included: demo-
graphic data, symptoms, initial disease stage, prog-
nostic factors, including weight loss and fitness, and 
therapeutic parameters of irradiation, including radiation 
dose, fractionation and total treatment time. Date of 
death was used as the data cut-off point. Every patient 
expressed and signed their informed consent to therapy 
with palliative intent. Detailed patient characteristics are 
presented in Table 1.
Treatment methods
Palliative radiation therapy was administered to all 
studied patients with non-small cell lung carcinoma. 
The areas of irradiation included lung tumour, meta-
static bone tumour and metastases to the CNS. Doses 
ranging from 6 Gy to 30 Gy were administered with 
a different fractionation regimen (1–10 fractions) and 
total treatment time (1–10 days). Systemic treatment 
was offered to all patients with stage IV NSCLC.
The total number of patients undergoing palliative 
radiation therapy was 3202, including 1762 patients 
with irradiation of a lung tumour (without distant metas-
tases), 548 patients with irradiation of brain metastases 
and 892 patients with irradiation of bone metastases. 
Table 1. Patient characteristics
Location of lesions
Number of patients  
(n = 3202)
Lung Bone CNS
Mean age 62.54 (22–93) 64.93 (22–93) 60.04 (30–89) 60.65 (36–87)
Sex (male/female) 2244/958 1300/462 596/296 348/200
Location of lesions Number  
of patients
Lung
6 Gy 19 (1%)
8 Gy 276 (16%)
10 Gy 0
20 Gy 1349 (76%)
30 Gy 118 (7%)
Bone
6 Gy 0
8 Gy 452 (51%)
10 Gy 30 (3%)
20 Gy 341 (38%)
30 Gy 69 (8%)
CNS
6 Gy 0  
8 Gy 0
10 Gy 0
20 Gy 476 (87%)
30 Gy 72 (13%)
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After the completion of radiation therapy, 100% of the 
treated patients of each group were followed-up for 
overall survival (OS). The three subgroups of patients 
were irradiated with different doses, which constituted 
a criterion of patient selection and follow-up for OS in 
these subgroups (Table 1). 
Statistical analysis
The arithmetic mean and median OS was calculated 
using the Microsoft Excel 2011 spreadsheet. Statistical 
significance of differences between the obtained results 
was checked using the logrank test (p < 0.05) in the 
STATISTICA software v. 13.0 by StatSoft. Comparative 
analysis of OS for all investigated groups was conduct-
ed using the Kaplan-Meyer method.
Results
Patients with irradiation of a lung tumour:
Median OS was 5–7 months after the completion of 
radiation therapy. The longest OS was observed in the 
group of patients irradiated with doses of 20 Gy (76%) 
and 30 Gy (7%). Patients who received lower single 
doses of 6 Gy (1%) and 8 Gy (16%) survived an insig-
nificantly shorter period, but this could be caused by 
the small size of the group and the patients’ individual 
disease characteristics (logrank test, p = 0.06) (Table 2, 
Fig. 1).
Patients with irradiation of bone metastases:
No significant differences in OS were observed 
between the employed fractionation regimens (Table 2, 
Fig. 2). The choice of a single radiation fraction for bone 
metastases not only resulted in a similar OS as with 
a higher dose administered in a few fractions but also 
allowed one-day treatment. 
Patients with irradiation of CNS metastases:
The choice of a higher dose of radiation therapy 
did not demonstrate differences in median OS values 
Table 2. OS values for the three subgroups of patients depending on the dose of radiation therapy and the location of 
the treated metastases
Lung
Dose/Number of patients 6 Gy
(n = 19)
8 Gy
(n = 276)
20 Gy
(n = 1349)
30 Gy
(n = 118)
Median OS (months) 6 5 7 7
Bone
Dose/Number of patients 8 Gy 
(n = 452)
10 Gy
(n = 30)
20 Gy
(n = 341)
30 Gy
(n = 69)
Median OS (months) 5 4 4 5
CNS
Dose/Number of patients – – 20 Gy  
(n = 476)
30 Gy 
(n = 72)
Median OS (months) – – 4 4
Figure 1. Kaplan-Meier survival curves for patients diagno-
sed with a lung tumor treated with palliative radiation 
therapy at different doses. Curves for each radiation dose 
have a very similar shape and course. The course is almost 
identical in the first 4 months and after the 14th month 
(most deaths occurred before the 14th month following the 
completion of radiation therapy). The small visible increase 
in the number of deaths of patients irradiated with the 6 Gy 
dose can be a result of a statistical error, as the group of 
patients irradiated with the 6 Gy dose is clearly smaller than 
the other groups. Individual patient characteristics could 
contribute to the results obtained in this small subgroup 
as well. In the 6th month, a large increase in the number 
of deaths in the group irradiated with the 30 Gy dose can 
be seen. The graphs for patients irradiated with the 8 and 
20 Gy doses are very similar throughout their continuity, 
with minor deviations seen only between the 5th and the 
6th month. Differences in the OS values for each subgroup 
of patients are statistically insignificant (logrank test, 
p = 0.06).
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compared to a lower dose. Based on the conducted 
analyses, it was found that increasing the total radiation 
dose does not extend the mean OS values (Table 2, 
Fig. 3). 
Discussion
Palliative radiation therapy administered in a single 
dose allows quickly obtaining the desired effect without 
exposing patients to prolonged therapeutic proce-
dures. Among the most common benefits of a single 
administration of a lower dose of radiation therapy in 
palliative treatment is its analgesic effect [7–8]. Often, 
bleeding from the upper respiratory ways in cases of 
tumours located in the lungs is stopped. The most fre-
quent reason for palliative radiation therapy in patients 
with NSCLC is hemoptysis that can be stopped with low 
doses administered at appropriate intervals [9]. 
In a study by Ma et al., a meta-analysis of random-
ized, controlled trials involving a total of 1730 patients 
with locally advanced lung cancer was conducted [10]. 
The aim of this meta-analysis was to compare a higher 
(≥ 30 Gy) and lower (< 30 Gy) dose of radiation ther-
apy in mitigating the symptoms and improving patient 
survival. The combined odds ratios (ORs) did not indi-
cate a significant difference in the mitigation of cough, 
chest pain and hemoptysis between groups subjected 
to radiation therapy at the higher and the lower dose. 
OS values after the 1st and the 2nd year were similar 
between the high-dose and low-dose groups. In an-
other retrospective study [11] involving 232 patients 
with NSCLC, the most frequently recommended dose 
was 2 fractions of 8.5 Gy (34%), followed by 10 frac-
tions of 3 Gy or equivalent doses (30%, EQD2 approx. 
33 Gy). OS was significantly shorter in the case of the 
2 × 8.5 Gy regimen (median OS 2.5 months compared 
to 5.0 months for the 33 Gy regimen). In our study, 
a greater range of therapeutic doses was used, but com-
parative analysis revealed similar conclusions regarding 
the benefits of lower doses of radiation therapy in the 
palliative treatment of locally advanced lung cancer. 
In the investigated subgroup of patients with irradi-
ation of bone metastases, no significant differences in 
OS were found. The choice of a single irradiation with 
a dose of 8 Gy in 1 fraction for bone metastases not only 
offers a similar OS, but also allows for further sessions 
of radiation therapy for the treatment of recurrent os-
teoarticular pain or improvement of neurological signs 
in cases of spinal cord compression, as well as for an 
effective reduction of symptoms caused by compres-
sion of neighboring organs by the tumor, bleeding or 
infiltration [12–16]. 
The acknowledged regimen for treating CNS me-
tastases is radiation therapy at 30 Gy in 10 fractions. In 
patients with poor prognosis, a smaller total dose of 
20 Gy in 5 fractions is used [17]. 
Figure 3. Kaplan-Meier survival curves for patients diagno- 
sed with CNS metastases of NSCLC treated with pallia-
tive radiation therapy at different doses. Curves for 
both doses are very similar. In both cases, most deaths 
occurred in the first 4 months. In the subsequent months 
of follow-up, the patients’ OS was similar (logrank test, 
p = 0.72). 
Figure 2. Kaplan-Meier survival curves for patients 
diagnosed with bone metastases of NSCLC treated with 
palliative radiation therapy at different doses. The course 
of four curves is comparable and illustrates the lack of a 
significant impact of dose level and fractionation on OS 
(logrank test, p = 0.88). Patients irradiated with the 10 Gy 
dose after the 4th month have a more flat curve than the 
other doses, with a proportionally lower death rate (a small 
number of deaths between the 4th and the 9th month). 
In the group of patients who received the 30 Gy dose, a 
sudden increase in the number of deaths in the 3rd month 
can be seen. Curves for the 8 and 20 Gy doses, the most 
commonly used doses in clinical practice, have a very 
similar course with minor deviations in each month. The 
similar course of curves for the groups irradiated with the 
8 Gy dose in 1 fraction and the 20 Gy dose in 5 fractions 
(OS = 5 months) should lead to the choice of irradiation 
in a single dose in these clinical cases.
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In our study, the choice of the higher dose of radi-
ation therapy did not demonstrate differences in OS 
compared to the lower dose (Fig. 3). Some researchers 
pointed out the doubtful results of reduced neurologi-
cal symptoms after palliative radiation therapy of brain 
metastases [18–20]. However, a better understanding 
of both the acute and the chronic toxicity of whole-brain 
radiation therapy should lead to more selective use of 
this procedure.
Conclusions
The use of a single fraction of palliative radiation 
therapy allows patients to conduct a single compre-
hensive hospital visit and obtain a therapeutic and 
analgesic effect, as well as to optimize their quality of 
life without the need for further hospital visits. In relation 
to the studied groups, the analysis should include the 
treatment cost and travel expenses that are lower with 
a single hospital visit. Therefore, due to the specificity 
of patients in palliative care and the progression of the 
disease, the selected therapeutic regimens should be 
as short as possible but effective, along with a rationally 
selected radiation dose.
The study demonstrated that the clinical effect of 
using high-dose irradiation is comparable to that of 
multi-fraction radiation therapy in palliative treatment.
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